Axsome Therapeutics Inc. (NASDAQ:AXSM)’s share price was down 5.8% during mid-day trading on Monday . The stock traded as low as $6.95 and last traded at $7.01, with a volume of 63,386 shares changing hands. The stock had previously closed at $7.44.

Several equities analysts have issued reports on AXSM shares. Cantor Fitzgerald set a $13.00 price objective on shares of Axsome Therapeutics and gave the company a “buy” rating in a research note on Wednesday, August 10th. Brean Capital reissued a “buy” rating and issued a $29.00 price objective on shares of Axsome Therapeutics in a research note on Thursday, May 12th. Finally, Zacks Investment Research raised shares of Axsome Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, July 27th.

The company’s market cap is $134.23 million. The firm has a 50-day moving average price of $7.67 and a 200-day moving average price of $8.50.

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the management of central nervous system (CNS) disorders, including pain. It operates in the business of developing novel therapies for the management of CNS disorders segment. Its product candidate, AXS-02 (disodium zoledronate tetrahydrate), is an oral, targeted, non opioid therapeutic for chronic pain.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.